Hemostemix (HEM) News Today C$0.08 +0.01 (+6.67%) As of 08/8/2025 01:15 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartHeadlinesInsider TradesBuy This Stock HEM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Hemostemix (CVE:HEM) Stock Price Down 25% - Here's What HappenedAugust 10 at 4:13 AM | americanbankingnews.comHemostemix (CVE:HEM) Stock Price Down 25% - What's Next?August 10 at 4:13 AM | americanbankingnews.comHemostemix (CVE:HEM) Stock Price Down 25% - Should You Sell?August 10 at 4:13 AM | americanbankingnews.comHemostemix (CVE:HEM) Shares Down 25% - Time to Sell?August 10 at 3:25 AM | americanbankingnews.comHemostemix (CVE:HEM) Shares Down 25% - Should You Sell?August 10 at 3:25 AM | americanbankingnews.comHemostemix (CVE:HEM) Trading Down 25% - What's Next?August 10 at 2:07 AM | americanbankingnews.comHemostemix (CVE:HEM) Trading Down 25% - Time to Sell?August 10 at 2:07 AM | americanbankingnews.comHemostemix (CVE:HEM) Trading Down 16.7% - Should You Sell?August 4, 2025 | americanbankingnews.comHemostemix (CVE:HEM) Stock Price Down 16.7% - Time to Sell?August 4, 2025 | americanbankingnews.comHemostemix (CVE:HEM) Shares Down 16.7% - Should You Sell?August 4, 2025 | americanbankingnews.comHemostemix (CVE:HEM) Trading Down 16.7% - Here's What HappenedAugust 4, 2025 | americanbankingnews.comHemostemix (CVE:HEM) Shares Down 16.7% - Here's What HappenedAugust 4, 2025 | americanbankingnews.comHemostemix (CVE:HEM) Trading Down 16.7% - Here's WhyAugust 4, 2025 | americanbankingnews.comHemostemix Increases Previously Closed Private Placement to $3,000,000August 1, 2025 | finance.yahoo.comCells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer ImplantsAugust 1, 2025 | finance.yahoo.comDirector buying at Hemostemix (HEM)July 30, 2025 | theglobeandmail.comHemostemix Closes Sale of 23rd ACP-01 Therapy Convertible DebentureJuly 24, 2025 | finance.yahoo.comHemostemix Closes $2,969,600 Private PlacementJuly 24, 2025 | finance.yahoo.comHemostemix Secures $2.97 Million in Private Placement to Boost OperationsJuly 24, 2025 | tipranks.comHemostemix Closing $3,000,000 Private PlacementJuly 17, 2025 | theglobeandmail.comHemostemix Oversubscribed, Closing $2,700,000 Private Placement and Settles $400,000 of Debt at $0.20 per ShareJuly 10, 2025 | finance.yahoo.comHemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial - Seeking AlphaJuly 5, 2025 | seekingalpha.comHemostemix Closes $469,366 Private PlacementJuly 4, 2025 | finance.yahoo.comHemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments! - Seeking AlphaJuly 3, 2025 | seekingalpha.comHemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!July 3, 2025 | finance.yahoo.comShares of Micro Cap Biotech Jump as New Law Opens Florida to Company’s Stem Cell TreatmentsJuly 3, 2025 | msn.comCroom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health LaunchJune 27, 2025 | finance.yahoo.comHemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible DebentureJune 26, 2025 | finance.yahoo.comHemostemix Closes Private Placement of $469,366June 17, 2025 | finance.yahoo.comHemostemix Presents at TERMIS 2025, Freiburg, GermanyMay 20, 2025 | theglobeandmail.comHemostemix Inc.May 12, 2025 | barrons.comHemostemix Closes Private Placement of USD $336,500 at $0.295 per ShareMay 12, 2025 | finance.yahoo.comHemostemix Secures $336,500 in Private Placement to Bolster GrowthMay 12, 2025 | tipranks.comHemostemix at Invest StuttgartMay 8, 2025 | finance.yahoo.comHemostemix Inc. (HEM.V)April 22, 2025 | finance.yahoo.comHemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical TrialMarch 17, 2025 | theglobeandmail.comInsider Buying: Hemostemix Inc. (CVE:HEM) Director Purchases 200,000 Shares of StockMarch 11, 2025 | insidertrades.comHemostemix Sells Its 23rd ACP-01 Therapy Convertible DebentureMarch 5, 2025 | finance.yahoo.comInsider Selling: Hemostemix Inc. (CVE:HEM) Director Sells 96,464 Shares of StockMarch 1, 2025 | insidertrades.comHemostemix Licenses CytoImmune's BioReactor TechnologiesFebruary 20, 2025 | finance.yahoo.comRETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor TechnologiesFebruary 20, 2025 | theglobeandmail.comHemostemix Inc. (HMTXF)February 16, 2025 | finance.yahoo.comHemostemix Provides Corporate UpdateFebruary 13, 2025 | finance.yahoo.comHemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma CertificationFebruary 11, 2025 | finance.yahoo.comHemostemix Announces First Sales Orders for ACP-01January 30, 2025 | finance.yahoo.comHemostemix Up-lists to TradeGateExchange in GermanyJanuary 27, 2025 | finance.yahoo.comHemostemix Up-Lists to OTCQB While it Presents its Global Scale-Up Strategy at Two Investor Conferences in Puerto RicoJanuary 23, 2025 | finance.yahoo.comHemostemix Announces Grant of Stock OptionsJanuary 21, 2025 | finance.yahoo.comHemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic ImpactJanuary 20, 2025 | finance.yahoo.comHemostemix Settlement via Depository Trust Company Plus OTCQB UpdateJanuary 14, 2025 | finance.yahoo.com Get Hemostemix News Delivered to You Automatically Sign up to receive the latest news and ratings for HEM and its competitors with MarketBeat's FREE daily newsletter. Email Address HEM Media Mentions By Week HEM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HEM News Sentiment▼0.220.48▲Average Medical News Sentiment HEM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HEM Articles This Week▼131▲HEM Articles Average Week Get Hemostemix News Delivered to You Automatically Sign up to receive the latest news and ratings for HEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Microbix Biosystems News Devonian Health Group News Sirona Biochem News Innovotech News Quest PharmaTech News Kane Biotech News Fennec Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:HEM) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemostemix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemostemix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale